Trading FDA, Clinical Trial Binary Events: $PPCO $DEPO $ENDP $IRIS $AGN

Below are some Regulatory Catalyst Index updates for companies with recent FDA and clinical trial related news…

Penwest Pharma (NASDAQ:PPCO) expects to report top-line results for a pair of ongoing Phase 2a studies by year-end 2010 with a goal of licensing A0001 (alpha-tocopherol-quinone) to a partner to complete / fund further clinical development and potential commercialization for Friedreich’s Ataxia and MELAS syndrome (neuro-muscular degenerative disorders).

DepoMed (NASDAQ:DEPO) expects to begin enrolling patients during 3Q10 for a pivotal Phase 3 (BREEZE) study of SERADA (extended release gabapentin) for the treatment of menopausal hot flashes while the Company expects a FDA decision during 1Q11 for its pending New Drug Application (NDA) for DM-1796 (extended release, once-daily gabapentin tablet formulation) to treat pain associated with shingles (post-herpetic neuralgia or PHN).

Below are summaries of the most recent articles written by Mark Messier at www.BioRunUp.com — please visit his website to read the full articles, in addition to many other free tools and strategies related to binary event investing and trading…

FDA Calendar Updates 8/6/10…ENDP – PDUFA for Fortesta 12/30/10 IRIS – 510K for NADiA ProsVue (prostate cancer test) ESTIMATED date of 10/29/10 AGN – sBLA for use of Botox for migraines 11/2/10…

www.mikehavRx.com is your prescription for stock index investing updates focused on the healthcare sector, medical innovation, and binary event tracking for FDA decisions and clinical trials, including 600+ events and 400+ companies with approximately 200 stocks trading under $5 per share and 80+ private companies. The home page includes an overview of the binary event tracking and personalized VIP services while the secure checkout page includes currently offered discount promo codes at https://mikehavrx.ssl.subhub.com/subscribe

Disclosure: No positions